Close
Nordic 9Nordic 9

Droia Ventures (investor - Venture Capital)

Luxembourg droiaventures.com
See something wrong or missing? Let us know
Offices:Luxembourg

Droia Ventures is an investor in Luxembourg focused on the development of oncology and genetic disease therapies.

Average round investment:45.5M USD
Average number per year:1.0
Distribution: 2023 (1)2020 (1)
Portfolio companies: Netherlands Vico Therapeutics
Mostly invests in: Netherlands Netherlands (2) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Droia Ventures

Name Criteria
United States Rick Klausner
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States New Science Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Belgium European Investment Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Benhamou Global Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Switzerland BioMedPartners
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Singapore Clay Capital
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Netherlands Meneldor
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Luxembourg Vesalius Biocapital Partners
81%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Lightstone Ventures
81%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Belgium SFPI-FPIM
81%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Top